XML 48 R31.htm IDEA: XBRL DOCUMENT v3.20.2
Results (Details) - EUR (€)
€ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2020
Jun. 30, 2019
Jun. 30, 2020
Jun. 30, 2019
Condensed Financial Statements, Captions [Line Items]        
Net loss € (115,042) € (47,249) € (165,643) € (95,905)
Operating loss (86,214) (44,367) (130,799) (97,610)
Research and development expenditure 149,114 € 94,372 265,877 177,567
G&A and S&M expenses     89,500 28,600
Fair value re-measurement of warrants € 589   21,118  
Net finance income (expense)     (13,000) 1,800
Net change in (fair) value of current financial investments     (12,484)  
Effect of exchange rate differences on cash and cash equivalents     (617) € 1,866
Increase (decrease) in personnel costs related to research and development     35,400  
Increase (decrease) in personnel costs related to general and administrative     € 31,300  
Cost Share For Global Development Activities 50.00% 20.00% 50.00% 20.00%
Effect of discounting long term deferred income     € 8,700  
Gilead        
Condensed Financial Statements, Captions [Line Items]        
Cost Share For Global Development Activities 50.00% 80.00% 50.00% 80.00%
Warrant B | Gilead        
Condensed Financial Statements, Captions [Line Items]        
Fair value re-measurement of warrants     € 21,100  
filgotinib, Toledo Program aAd Other Clinical Programs [Member]        
Condensed Financial Statements, Captions [Line Items]        
Increase in subcontracting costs classified as R&D expenses     € 42,700